{"filings":[{"id":50681,"accession_number":"0001193125-26-220697","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2026-05-13T12:35:15+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lite Strategy reports $0.7M yield from LTC covered calls, repurchases 1.6M shares","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Generated $0.7M net proceeds from covered call program on LTC holdings since Oct 2025.","Repurchased 1,629,136 shares using covered call proceeds and 35,250 LTC since Oct 2025.","SEC issued March 2026 guidance indicating LTC exhibits characteristics of a digital commodity.","Plans to continue scaling covered call program and executing on $25M share repurchase authorization.","Pharmaceutical operations advancing pre-clinical programs as potential non-dilutive capital source."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102170,"accession_number":"0001193125-26-053243","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lite Strategy Q2 results: $600k from covered call program, launches $25M buyback","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Generated ~$600,000 in gross premiums from covered call options on LTC holdings.","Commenced $25 million stock repurchase program funded by treasury operations.","Held $8.8 million in cash as of Dec 31, 2025; initiated pre-clinical R&D in non-oncology.","Management focuses on transforming LTC into productive reserve asset via active strategies."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102169,"accession_number":"0001193125-26-049005","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 2026 equity plan and elect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved the 2026 Omnibus Equity Compensation Plan, authorizing up to 2,000,000 new shares for equity grants.","Approval triggered previously disclosed grant of options to CEO Justin File for 455,000 shares.","Directors Justin File and Joshua Riezman re-elected with ~7.55M votes for each; ~4.78M withheld.","Advisory vote on executive compensation passed with 6,006,580 for, 5,538,689 against (49% in favor).","Ratification of CBIZ CPAs as auditor approved with 18,939,953 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118485,"accession_number":"0001193125-25-335761","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lite Strategy finalizes CEO Justin File employment agreement with $575K base salary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Agreement dated Dec 23, 2025, effective Nov 14; replaces prior agreement.","Base salary $575,000; target annual bonus of 50% base salary ($284,375).","Severance: 12 months salary, COBRA for 12 months, pro-rata bonus, 12-month stock option acceleration.","Full acceleration of outstanding options on change in control within 2 years or 3 months before.","Justin File also continues as CFO and Secretary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118484,"accession_number":"0001193125-25-309593","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Lite Strategy dismisses Deloitte, appoints CBIZ CPAs as auditor for FY2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed Deloitte & Touche LLP and engaged CBIZ CPAs P.C. as independent auditor effective December 2, 2025.","No 'disagreements' or 'reportable events' occurred with Deloitte during fiscal 2024, 2025, or through Sept 30, 2025.","Deloitte's audit reports for FY2025 and FY2024 were unqualified; no adverse opinions or scope limitations.","The change was not due to any disagreement between the company and Deloitte."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118481,"accession_number":"0001193125-25-290059","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K/A","filed_at":"2025-11-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lite Strategy corrects CEO option grant; grants 455K replacement options at $2.02","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Corrects original 8-K: CEO Justin File received 180,000 options, not 635,000 as previously reported.","Board approved 455,000 replacement options to File on Nov. 20, 2025, exercising at $2.02 per share.","Replacement options contingent on stockholder approval of new omnibus equity plan at 2026 annual meeting.","Replacement options vest on same schedule as the 180,000 options granted Nov. 14, 2025; cancelled if plan not approved.","No other changes to original filing; amendment only addresses option grant disclosure error."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118483,"accession_number":"0001193125-25-286424","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lite Strategy appoints Justin J. File as permanent CEO and grants 635K options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Justin J. File, previously Acting CEO and CFO/Secretary, named permanent CEO effective Nov 14, 2025.","File also appointed to the Board, serving until 2026 Annual Meeting.","Granted options for 635,000 shares at $2.02, vesting over 36 months starting Dec 14, 2025.","File continues as CFO and Secretary; no additional compensation for board service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118482,"accession_number":"0001193125-25-258474","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Lite Strategy authorizes $25M share repurchase; director Reynolds resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized $25M share repurchase program, effective immediately, through open market or negotiated transactions.","Company holds ~1M Litecoin treasury; buyback used at discount to mNAV; ATM used at premium to acquire more Litecoin.","Director Thomas C. Reynolds, M.D., Ph.D. resigns effective Nov 4, 2025; no disagreement with company.","Repurchase program is not obligated and may be suspended; finances via working capital; possible 10b5-1 plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134928,"accession_number":"0001193125-25-203520","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Investor exercises 1.595M pre-funded warrants in cashless exercise for 1.594M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Sept 10, 2025, an investor exercised 1,595,000 pre-funded warrants issued at $3.4199 each in a cashless exercise.","The exercise resulted in the issuance of 1,594,944 shares of common stock (ticker: LITS).","Warrants were originally issued in a private placement on July 22, 2025, with total warrants for 6,022,869 shares.","Exemption from registration relied on Section 4(a)(2) and Rule 506(b) of Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134934,"accession_number":"0001262104-25-000009","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"MEI Pharma rebrands as Lite Strategy, Inc., adopts digital asset treasury with LTC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company changes name to Lite Strategy, Inc.; NASDAQ ticker changes from MEIP to LITS effective Sep 11, 2025.","Holds over $100M in Litecoin (LTC) as primary reserve asset; advised by GSR for liquidity and risk management.","LTC creator Charlie Lee joins board; continues preclinical evaluation of voruciclib and zandelisib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134933,"accession_number":"0000929638-25-003398","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"MEI Pharma enters Master Loan Agreement with BitGo Prime for digital asset and USD borrowings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Master Loan Agreement with BitGo Prime allows MEI to borrow digital assets or USD, secured by collateral.","Terms (principal, fee, maturity, call/prepayment) set per loan in confirmations; loans can be fixed-term, callable, or prepayable.","Collateral required at initial margin; margin call provisions apply; failure can trigger liquidation.","Loan fee annualized, calculated daily; late fee 12% annualized; early termination fee 20% of remaining loan fee for fixed-term loans.","Agreement creates borrowing framework; no actual borrowings disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134932,"accession_number":"0000950170-25-103990","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Steven Wood resigns; Joshua Riezman elected to MEI Pharma board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven D. Wood resigned from the board effective August 5, 2025; no disagreement cited.","Board elected Joshua Riezman, Managing Director and Head of U.S. Legal & Compliance at GSR Strategies.","GSR is the asset manager under the July 22, 2025 Asset Management Agreement with MEI Pharma.","Riezman will be compensated under existing non-employee director arrangements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134931,"accession_number":"0000950170-25-102419","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MEI Pharma acquires ~$110M in Litecoin, becomes first US-listed company to adopt LTC as primary reserve","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquired 929,548 LTC tokens at avg price $107.58; LTC treasury valued at ~$110.4M as of Aug 4, 2025.","Deployed all net proceeds from July 17, 2025 PIPE Offering with Titan Partners as placement agent.","Strategy developed with GSR; Litecoin creator Charlie Lee (MEI board member) providing guidance.","Company plans to update corporate identity and may start Litecoin mining; continues pre-clinical drug pipeline voruciclib.","First US-listed public company to adopt Litecoin as primary reserve asset for treasury strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134930,"accession_number":"0000950170-25-100341","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"MEI Pharma reports exercise of pre-funded warrants for 2.08M shares of common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Investor exercised Pre-Funded Warrants to purchase 2,084,509 shares of common stock on July 24, 2025.","Exercise price paid in cash was $208.45 in aggregate, representing a nominal per-share price.","Warrants were issued under the PIPE Offering initially disclosed on July 17, 2025, with exercise price of $3.4199 per warrant.","Shares were issued in reliance on Section 4(a)(2) and Rule 506(b) of Regulation D exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134929,"accession_number":"0001140361-25-026773","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["1.01","1.02","5.02","3.02","8.01","9.01"],"status":"ready","headline":"MEI Pharma Raises $100M in PIPE to Launch Litecoin Treasury Strategy; Charlie Lee Appointed to Board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$100M from sale of 29.2M shares/pre-funded warrants at $3.42 per share.","100% of net proceeds to be used to acquire Litecoin (LTC), making MEI first public company to hold LTC as treasury asset.","Charlie Lee, Litecoin creator, appointed to Board; Taheer Datoo resigns per Cooperation Agreement.","GSR Strategies LLC appointed as Asset Manager; Green Dragon Investments LLC as advisor under separate agreements.","Also entered into $100M ATM sales agreement with Titan; terminated prior ATM facility with JonesTrading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151883,"accession_number":"0000950170-25-070298","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MEI Pharma reports $20.5M cash; strategic alternatives review ongoing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and cash equivalents $20.5M as of March 31, 2025, with no outstanding debt.","Strategic alternatives review continues since July 2024; Oppenheimer & Co. serving as exclusive financial advisor.","Reduction-in-force progressing in stages as operational and strategic direction evolves.","No assurance any transaction will result; updates only if completed or legally required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170742,"accession_number":"0000950170-25-035544","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MEI Pharma amends CEO Justin File's employment agreement; base salary $550,000, retention bonus $412,500","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary $550,000 (eff Aug 1, 2024); target bonus 50% of base salary for FY2025.","Retention bonus $412,500 payable upon Change in Control, termination w/o cause, board dissolution approval, or Sep 30, 2025.","Success fee equal to 10% of net absolute cash retention vs forecast, measured as of Mar 31, 2025 or earlier events.","Severance includes 12 months base salary, $70,669 lump sum, pro-rata bonus, and accelerated stock option vesting.","Term through Sep 30, 2025; full option vesting upon qualifying termination within 2 years after Change in Control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170741,"accession_number":"0000950170-25-018820","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MEI Pharma reports $23.7M cash, no debt, continues strategic alternatives review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and cash equivalents $23.7M as of Dec 31, 2024; no outstanding debt.","Strategic alternative evaluation ongoing, including out-licensing and M&A; Oppenheimer & Co. as financial advisor.","Cash preservation efforts underway, including staged reduction-in-force.","No assurance that the strategic review will result in any transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170740,"accession_number":"0000950170-25-011790","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MEI Pharma annual meeting results: directors elected, say-on-pay approved, auditors ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Frederick W. Driscoll and Nicholas R. Glover elected as directors with 2,360,948 and 2,722,093 votes for, respectively.","Advisory vote on executive compensation approved: 2,127,143 for, 456,162 against, 619,897 abstain.","Ratification of Deloitte & Touche LLP as independent auditor for FY2025 approved: 4,255,692 for, 33,846 against, 10,400 abstain.","Total 4,299,938 shares represented at the meeting out of 6,662,857 outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187708,"accession_number":"0000950170-24-130593","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"MEI Pharma sets 2025 annual meeting for Jan 30, 2025; record date Dec 9, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2025 Annual Meeting to be held on January 30, 2025.","Stockholders of record as of December 9, 2024 entitled to vote.","Deadline for Rule 14a-8 shareholder proposals is December 10, 2024.","Deadline for director nominations outside Rule 14a-8 (Sept 18, 2024) has passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187707,"accession_number":"0000950170-24-127054","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MEI Pharma reports $26.9M cash, no debt; continues strategic alternatives review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and short-term investments at Sept 30, 2024: $26.9M; no outstanding debt.","Strategic alternatives review ongoing; Oppenheimer & Co. acting as exclusive financial advisor.","Reduction-in-force initiated as part of cash preservation efforts; further stages planned.","No assurance that any transaction will result; updates only if Board determines disclosure appropriate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187706,"accession_number":"0000950170-24-117406","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"MEI Pharma sells rights to ME-344 to Aardvark Therapeutics for up to $62.5M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed on Oct 22, 2024: sold ME-344 assets (IP, contracts, technology) to Aardvark Therapeutics for $0.5M upfront plus $55K reimbursement.","Potential milestone payments up to $62M tied to regulatory approval and sales milestones for ME-344.","Purchaser assumes certain liabilities under transferred contracts; no material relationship between parties.","Company retains all other assets and liabilities not specifically transferred (Excluded Assets and Liabilities)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204203,"accession_number":"0000950170-24-108171","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MEI Pharma reports $38.3M cash; continues evaluating strategic alternatives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents, and short-term investments at June 30, 2024: $38.3 million, with no outstanding debt.","Board commenced evaluation of strategic alternatives on July 22, 2024; Oppenheimer & Co. retained as exclusive financial adviser.","Reduction-in-force commenced August 1, 2024, continuing in stages; clinical development of voruciclib discontinued.","Options include out-licensing programs and M&A; company will not disclose developments unless completed or required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204202,"accession_number":"0000950170-24-089939","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO and CMO depart; MEI Pharma evaluates wind-down; CFO becomes Acting CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO David M. Urso and CMO Richard G. Ghalie depart effective Aug 1, 2024; eligible for severance (12 mo salary, COBRA, prorated bonus, accelerated vesting).","Executives signed consulting agreements ($475/hr) to assist asset sales; Urso eligible for 8% success fee, Ghalie 2% on net proceeds from voruciclib, ME-344, zandelisib.","CFO Justin J. File appointed Acting CEO; base salary raised to $550k, bonus target increased to 50%, and eligible for success fee based on closing cash balance.","Company continues evaluating strategic alternatives including possible wind-down to maximize asset value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204201,"accession_number":"0000950170-24-087841","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"MEI Pharma halts voruciclib clinical development, begins strategic alternatives review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board unanimously decided to evaluate strategic alternatives including potential transactions or orderly wind-down.","Clinical development of voruciclib discontinued; only certain non-clinical activities will continue.","Company intends to maximize value of its assets; no specific timeline or deal announced.","Corporate presentation attached as Exhibit 99.1 details voruciclib program status."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204200,"accession_number":"0000950170-24-085347","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["2.05","5.02","7.01","9.01"],"status":"ready","headline":"MEI Pharma halts voruciclib, cuts workforce, CEO/CMO depart, evaluates wind-down","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board unanimously begins evaluation of strategic alternatives including transactions or orderly wind-down.","Reduction-in-force commencing; clinical development of voruciclib discontinued.","CEO David Urso and CMO Richard Ghalie step down Aug 1, 2024; CFO Justin File appointed Acting CEO.","Expected restructuring charges of ~$5.8 million in Q1 fiscal 2025 for one-time employee termination costs.","Charles Baltic steps down as Chairperson; Frederick Driscoll appointed as Chair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220936,"accession_number":"0000929638-24-002259","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MEI Pharma terminates office lease; pays $11.1M fee, saves $2.6M/year","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease at 11455 El Camino Real, San Diego terminated as of Sept 30, 2024 (original expiry Nov 30, 2029).","Termination fee of ~$11.1M; savings over lease term of ~$3.7M before fees.","Annual operating expenses reduced by ~$2.6M; company believes resources sufficient for ≥12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220935,"accession_number":"0000950170-24-062739","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MEI Pharma presents voruciclib Phase 1b AML data at Brookline Symposium","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CMO Richard Ghalie discussed voruciclib clinical data at virtual MDS/AML symposium on May 21, 2024.","Voruciclib is an oral CDK inhibitor; ongoing Phase 1b in relapsed/refractory AML targeting resistance mechanisms.","Specific efficacy/safety results are detailed in the attached corporate presentation (Exhibit 99.1) but not excerpted in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220934,"accession_number":"0000950170-24-056850","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MEI Pharma reports Q3 FY2024 cash $56.6M, no revenue; prioritizes voruciclib program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents & investments $56.6M at Mar 31, 2024; no revenue for Q3 vs $5.9M prior year.","R&D expenses $5.2M (down from $15.1M YoY) due to zandelisib wind-down; G&A $4.6M (down from $7.2M).","Voruciclib Phase 1 expansion cohort enrolling; complete responses observed in R/R AML patients.","Board unanimously prioritizes voruciclib, decides against second return of capital under cooperation agreement.","ME-344 formulation development initiated; update expected in first half of calendar 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":5.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":65297000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240531,"accession_number":"0000950170-24-017875","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MEI Pharma signs $25M ATM equity facility, initially capped at $10.3M due to float limit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into Capital on Demand Sales Agreement with JonesTrading to sell up to $25M of common stock in ATM offerings.","Initial offering limit is $10.3M because public float is under $75M; may increase if float grows.","Also filed a universal Form S-3 registration statement for up to $100M in securities.","Agent commission is 3.0% of gross proceeds from shares sold under the agreement.","No assurance any shares will be issued; agreement can be terminated by either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240530,"accession_number":"0000950170-24-014643","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MEI Pharma reports Q2 FY2024 results; cash $59.5M, zero revenue, clinical data readouts expected H1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and short-term investments of $59.5M at Dec 31, 2023, with no outstanding debt.","Revenue zero for Q2 ended Dec 31, 2023 vs $32.7M prior year due to Kyowa Kirin agreement termination.","R&D expenses fell to $3.9M in Q2 from $15.3M Q2 prior year, driven by zandelisib program wind-down.","Expects initial safety/efficacy data for voruciclib (CDK9 inhibitor) and ME-344 (mitochondrial inhibitor) in first half of 2024.","Cash used in operations was $29.5M for six months ended Dec 31, 2023, comparable to $29.1M prior period."],"consensus_eps_estimate":-1.4637,"consensus_eps_actual":6.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":65297000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240529,"accession_number":"0000950170-24-005013","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MEI Pharma enters new CMO employment agreement; $503K salary, 40% bonus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Richard Ghalie continues as CMO under new agreement effective Jan 16, 2024; base salary $503,165.28, target bonus 40% of base.","Termination without cause or for good reason: lump sum 12 months base, COBRA for 12 months, pro-rata bonus, 12-month option vesting acceleration.","Change in control: full vesting of options if terminated without cause in 3 months before or 2 years after CIC.","Death or disability triggers additional 12-month option vesting acceleration.","Agreement aligns terms with other senior executives; replaces prior 2016 employment letter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258042,"accession_number":"0000950170-23-073079","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-12-26T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"MEI Pharma dismisses BDO as auditor, appoints Deloitte effective Dec 26, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed BDO USA, P.C. as independent auditor on Dec 19, 2023; no adverse opinions or disagreements in recent fiscal years.","Appointed Deloitte & Touche LLP as new auditor effective Dec 26, 2023 after a competitive selection process.","Previously reported material weakness in internal controls over revenue recognition was remediated as of June 30, 2023.","BDO furnished a letter agreeing with the company's statements, filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258041,"accession_number":"0000950170-23-072612","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"MEI Pharma adopts Sixth Amended and Restated Bylaws effective December 18, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board designated at eight directors; amendments conform to revised DGCL.","Changes include updated meeting notice rules, adjourned meetings, record date.","Board may now designate any person (not just officers) to chair stockholder meetings.","Director removal standard aligned with DGCL and Certificate of Incorporation.","Administrative updates: gender-neutral terms, waiver by electronic transmission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258040,"accession_number":"0000950170-23-071066","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MEI Pharma stockholders elect directors and approve say-on-pay at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected James Flynn, Taheer Datoo, and Steven Wood to three-year board terms.","Advisory vote on executive compensation approved with 2,510,335 votes for and 149,459 against.","Advisory vote on frequency of say-on-pay set at 1 year with 2,534,092 votes for 1 year.","Ratification of BDO USA as independent auditor approved with 4,366,180 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258039,"accession_number":"0000950170-23-069381","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MEI Pharma reports clinical data on oral CDK9 inhibitor voruciclib at ASH2023; safety profile well-tolerated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voruciclib monotherapy up to 200 mg on intermittent schedule well-tolerated; no DLTs. Common AEs: diarrhea, nausea, anemia, fatigue.","On-target Mcl-1 and RNA Pol II p-S2 reductions demonstrated in correlative pharmacodynamic studies.","In AML monotherapy: 1 patient achieved morphologic leukemia-free state; 9 had stable disease (2 for ≥3 months).","In B-cell malignancies: 4 patients had stable disease with tumor size decrease.","Combination with venetoclax ongoing; no DLTs or overlapping toxicity; anti-tumor activity observed with multiple patients on therapy ≥4 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258038,"accession_number":"0000950170-23-062017","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MEI Pharma Q1 net income $56.4M on deferred revenue; clinical trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $56.4M ($8.46 EPS) vs prior-year net loss $16.6M; revenue $65.3M from Kyowa Kirin termination.","Cash $82.2M with no debt; operating cash burn $18.5M; funds operations for at least 12 months through data readouts.","Voruciclib (CDK9) Phase 1 combo with venetoclax dose-escalation data expected early 2024.","ME-344 (mitochondrial inhibitor) Phase 1b combo with bevacizumab first-cohort data expected H1 2024.","Abstract on voruciclib monotherapy dose escalation to be presented at ASH Dec 9-12, 2023."],"consensus_eps_estimate":-1.5504,"consensus_eps_actual":8.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":65297000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258037,"accession_number":"0001193125-23-268167","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"MEI Pharma reaches deal with activist investors; declares $1.75/share dividend, adds three new directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Immediate dividend of $1.75 per share paid to all stockholders; potential additional $9.33M return contingent on ME-344 trial results or Board decision.","Three new directors appointed: James Flynn, Taheer Datoo (Anson/Cable Car designees) and Steven Wood (mutual). Three former directors resigned.","Board forms Capital Allocation Committee to advise on strategic capital allocation for drug programs and value creation.","Investors agree to standstill, withdraw consent solicitation, and vote for Company slate at 2024 and 2025 annual meetings.","Agreement aims to avoid proxy contest; Company expects near-term data readouts for voruciclib and ME-344 in first half 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258036,"accession_number":"0001193125-23-249423","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-10-03T23:59:59+00:00","items":["1.01","3.03","5.03","7.01","9.01"],"status":"ready","headline":"MEI Pharma adopts poison pill after Anson/Cable Car accumulate ~19.9% stake","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rights plan triggers at 20% ownership; expires September 30, 2024.","Anson Advisors and Cable Car Capital hold ~19.9% of MEIP shares and sold put options for 1.5M additional shares.","Existing holders above 20% are grandfathered but cannot increase ownership without triggering plan.","Upon trigger, non-acquiring holders may purchase shares at twice the exercise price, causing dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275357,"accession_number":"0001193125-23-242526","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MEI Pharma FY2023 net loss $31.8M; cash $100.7M; merger fails, CEO changed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $31.8M ($4.78/share) vs $54.5M ($8.75/share) prior year; revenue $48.8M, up from $40.7M.","Cash and equivalents $100.7M, no debt; cash used in operations $52.5M.","Stockholders rejected Infinity Pharmaceuticals merger (47.86% for, 51.44% against); agreement terminated.","David M. Urso appointed CEO (June 2023); Jay File appointed CFO (effective Aug 2023).","Voruciclib+venetoclax data early 2024; ME-344+bevacizumab data H1 2024; workforce reduced 61% to 41 employees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275356,"accession_number":"0001193125-23-196279","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MEI Pharma promotes Justin File to CFO; Brian Drazba departs without cause","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Justin J. File appointed CFO and Corporate Secretary effective August 1, 2023.","Brian Drazba's employment as CFO terminated without cause on same date.","Drazba receives severance of $428,635 (12 months base salary), COBRA subsidy for 12 months, and accelerated stock option vesting.","Transition previously disclosed on June 13, 2023; Drazba remains through Separation Date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275355,"accession_number":"0001193125-23-191945","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["1.02","5.07","8.01","9.01"],"status":"ready","headline":"MEI Pharma terminates merger with Infinity after stockholder vote fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders voted against merger: 47.86% for, 51.44% against; turnout 59.70% of outstanding shares.","MEI terminated the Merger Agreement with Infinity on July 23, 2023, effective immediately.","Company will continue development of Voruciclib and ME-344; clinical data expected around year-end.","CEO David M. Urso stated focus on capturing stockholder value from pipeline programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275354,"accession_number":"0001193125-23-189610","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["1.02","8.01","9.01"],"status":"ready","headline":"MEI Pharma terminates Kyowa Kirin deal, regains full global rights to ME-401; urges vote for Infinity merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mutually terminated License, Development and Commercialization Agreement with Kyowa Kirin for ME-401 effective July 14, 2023.","MEI regains full global rights to develop, manufacture and commercialize ME-401; Kyowa Kirin retains limited compassionate use until Nov 30, 2027.","Each party released the other from claims; MEI must deliver certain materials to Kyowa Kirin.","Press release reminds shareholders to vote FOR Infinity transaction at July 23 special meeting; ISS and Glass Lewis recommend FOR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275353,"accession_number":"0001193125-23-188930","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MEI Pharma rejects activist consent solicitation to remove board without cause under Delaware law","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anson Advisors and Cable Car Capital launched consent solicitation on July 17, 2023 to remove all directors without cause and repeal recent bylaw amendments.","MEI states removal proposal is invalid under Delaware law because classified board directors may only be removed for cause; charter does not provide otherwise.","Bylaw proposal is unnecessary as no bylaw amendments have been made since February 23, 2023, and board has no current intent to amend.","Board urges shareholders to vote FOR the pending Infinity Pharmaceuticals merger, endorsed by ISS and Glass Lewis.","Company reserves the right to contest any solicitation or actions taken in connection with the invalid proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275352,"accession_number":"0001193125-23-188090","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-07-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MEI Pharma urges shareholders to vote FOR Infinity merger ahead of July 23 special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MEI mailed letter to shareholders on July 17, 2023, pleading vote FOR the Infinity (INFI) merger at the July 23 special meeting.","Combined company would hold three clinical-stage assets: Eganelisib, Voruciclib, ME-344 with data catalysts in 6-24 months.","ISS and Glass Lewis both recommend FOR; ISS reiterated its support as recently as July 14, 2023.","MEI claims the deal creates a well-capitalized pipeline and leverages the clinical expertise of both teams."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275351,"accession_number":"0001193125-23-186570","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MEI Pharma postpones special meeting on Infinity merger to July 23, 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting postponed from original date to July 23, 2023 at 10:00 a.m. ET; may be further adjourned.","Infinity exercised its contractual right to require the postponement under the merger agreement.","MEI board continues to recommend shareholders vote FOR the transaction with Infinity.","Record date remains May 24, 2023; ISS and Glass Lewis recommend FOR the deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275350,"accession_number":"0001193125-23-183853","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-07-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Glass Lewis joins ISS in recommending MEI Pharma shareholders vote FOR Infinity merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Both ISS and Glass Lewis recommend shareholders vote FOR the Infinity merger.","Special meeting to approve merger scheduled for July 14, 2023.","Combined company expected to have cash to fund pipeline through 2025.","Shareholders of record as of May 24, 2023 are eligible to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275349,"accession_number":"0001193125-23-182031","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ISS recommends MEI Pharma shareholders vote FOR merger with Infinity Pharma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Independent proxy advisory ISS recommends voting FOR the Infinity merger at July 14 special meeting.","MEI board reiterates support, citing potential to create diversified three-program clinical pipeline.","Combined company expects key clinical data from both MEI programs by year-end 2023.","Shareholders of record as of May 24, 2023 are eligible to vote.","Alliance Advisors is proxy solicitor; Stifel and Morgan Lewis are advisors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292835,"accession_number":"0001193125-23-178569","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MEI Pharma urges shareholders to vote FOR Infinity merger ahead of July 14 special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board reiterates recommendation to approve merger with Infinity Pharmaceuticals (INFI) at July 14 special meeting.","Combined pipeline includes three clinical-stage programs: eganelisib, voruciclib (with Venclexta), and ME-344 (with Avastin).","Key data expected from voruciclib and ME-344 by year-end 2023; eganelisib is a Phase 2 first-in-class PI3K-gamma inhibitor.","Combined company will have experienced drug development team and is positioned to advance diversified oncology pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292834,"accession_number":"0001193125-23-176628","cik":1262104,"company_name":"Lite Strategy, Inc.","ticker":"LITS","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MEI Pharma Board Rejects Anson/Cable Car Unsolicited Bid, Reaffirms Infinity Merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board unanimously rejects unsolicited, non-binding proposal from Anson Advisors and Cable Car Capital as undervaluing the Company.","Proposal was at a significant discount to MEI's cash position; Board sees no basis for discussions on an alternative transaction.","Board reaffirms recommendation for pending merger with Infinity; combined pipeline of three clinical-stage programs.","Key clinical data from combined pipeline expected in 6-24 months, including from two programs by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32990833.92,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-06-28T23:59:59+00:00|292834"}